NCT04203914 (EMPHYT) is a Phase 4 clinical trial of Empagliflozin Tablets in Hypertension, sponsored by Yaounde Central Hospital.

Who is sponsoring NCT04203914?

NCT04203914 is sponsored by Yaounde Central Hospital.

What drugs are being tested in NCT04203914?

Interventions in NCT04203914: Empagliflozin Tablets.

What condition does NCT04203914 study?

NCT04203914 studies Hypertension.

Is NCT04203914 still recruiting?

NCT04203914 is currently completed. Last updated 23 December 2019.

Last reviewed 2019-12-23 · How we verify

NCT04203914: EMPHYT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short Term Effect of Empagliflozin in Hypertension

Completed Phase 4 Last updated 23 December 2019

What this trial tests

Phase 4 trial testing Empagliflozin Tablets in Hypertension in 15 participants. Completed in 30 September 2017.

Timeline

10 January 2017

Primary endpoint
30 May 2017

30 September 2017

Quick facts

Lead sponsor	Yaounde Central Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	10 January 2017
Primary completion	30 May 2017
Estimated completion	30 September 2017
Sites	2 locations across Cameroon

Drugs / interventions tested

Empagliflozin Tablets — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Yaounde Central Hospital

Who can join

21 and older, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Empagliflozin Tablets

Trials testing the same drug.

NCT06643442 — Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age · Phase 2 · not yet recruiting
NCT04221152 — A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) · Phase 3 · unknown
NCT04018365 — A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance · Phase 3 · unknown
NCT03771781 — Bioequivalence Study of Empagliflozin Tablet in Healthy Participants. · NA · completed

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Yaounde Central Hospital trials

Trials by the same sponsor.

NCT04790214 — Effect of a Cardiac Rehabilitation Program on Chronic Heart Failure Patients in Yaoundé, Cameroon · NA · unknown
NCT04715295 — Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19 · Phase 4 · unknown
NCT05013346 — Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study · unknown
NCT04255992 — Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypert · Phase 4 · completed
NCT04254042 — Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Pat · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04203914 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yaounde Central Hospital
Last refreshed: 23 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04203914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing